Phase 2 study of zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies (DLB).

ABSTRACT:

Introduction

Zervimesine is in clinical development for Alzheimer's disease and dementia with Lewy bodies (DLB). This Phase 2a study evaluated zervimesine in participants with mild-to-moderate DLB.

Methods

This was a multi-center, double-blind, placebo-controlled, parallel-design study. Participants aged 50 to 85 years, with probable DLB, a Mini-Mental State Examination score of 18 to 27, and without neurological co-morbidities were randomized to zervimesine 100 mg, zervimesine 300 mg, or placebo for 26 weeks to assess safety and efficacy.

Results

Of 293 participants screened, 130 were randomized, and 109 (83.8%) completed the study. Baseline characteristics were similar between groups. Discontinuation rates for adverse events were 4.5% for zervimesine 100 mg, 16.3% f

SUBMITTER: Galvin JE 

PROVIDER: S-EPMC12715698 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature